 | • レポートコード：B-MOR-040917 • 出版社/出版日：Mordor Intelligence / 2018年2月 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：医療・バイオ |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、抗毒素の世界市場について調べ、抗毒素の世界規模、市場動向、市場環境、動物別（ヘビ、サソリ、クモ、その他）分析、タイプ別（異種の多価抗毒素、異種の一価抗毒素、同種の抗毒素、小分子抗毒薬）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・抗毒素の世界市場インサイト ・抗毒素の世界市場環境 ・抗毒素の世界市場動向 ・抗毒素の世界市場規模 ・抗毒素の世界市場規模：動物別（ヘビ、サソリ、クモ、その他） ・抗毒素の世界市場規模：タイプ別（異種の多価抗毒素、異種の一価抗毒素、同種の抗毒素、小分子抗毒薬） ・抗毒素の世界市場：地域別市場規模・分析 ・抗毒素の北米市場規模・予測 ・抗毒素のアメリカ市場規模・予測 ・抗毒素のヨーロッパ市場規模・予測 ・抗毒素のアジア市場規模・予測 ・抗毒素の日本市場規模・予測 ・抗毒素の中国市場規模・予測 ・抗毒素のインド市場規模・予測 ・抗毒素の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global antivenoms market has been estimated to reach USD 152.31 million in 2017.The market is expected to register a CAGR of 4.4% during the forecast period 2018 to 2023. North America is dominating the market due to increasing antivenom products and research & development for effective antivenom products in that region.
Increasing Awareness on Antivenoms Available
Snake bite is a neglected public health issue in many tropical and subtropical countries. About 5 million snake bites occur each year, resulting in up to 2.5 million envenoming’s (poisoning from snake bites), at least 100 000 deaths and around three times as many amputations and other permanent disabilities. But due to the involvement of international health organizations for producing safe and effective antivenoms people are aware about such antivenoms drugs.
Additionally, recent advancement in pharmaceuticals is also fuelling the global antivenom market.
High Cost of Available Antivenoms
Antivenom production is difficult and expensive. The cost of some antivenom has increased dramatically over the last two decades, making treatment unaffordable for most of the people who need it. Increasing prices have suppressed demand and the treatment has declined significantly, or disappeared entirely in some areas. Inappropriate procurement and medicine distribution strategies in few countries contribute to manufacturers ceasing the production of antivenom or increasing the prices of antivenom. The high cost of the drug, which is around USD 540 per four vial treatment is an example to say that the product never reached many people who cannot afford the treatment.
Also, preparation of the correct immunogens (snake venoms), lack of regulatory capacity for the control of antivenoms in countries, and weak health systems and lack of data are acting restraints the Global Antivenom market.
North America to Dominate the Market
The Global Antivenom Market is segmented into by animals (snakes, scorpion, spiders and others), by type of antivenoms (polyvalent heterologous, monovalent heterologous, homologous and small molecule anti-toxins) and geography. . By geography it is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa and South America.
North America contributes a major share in antivenom market due to the establishment of snake poison control centers, increase in antivenom products and rise in clinical trial conducting firms for antivenom products and established healthcare facilities in that region.
Key Developments in the Market
• September 2017: BTGs CroFab (crotalidae polyvalent immune fab (ovine)), a drug is approved in the US for the treatment of the North American Crotalid snakebites.
• May 2017: Snakebite911, an app that contain educational information on snakes and snakes bite first aid support which is developed by BTG plc.
Key players: PFIZER INC, BIOCLON INSTITUTE, CSL LIMITED, BTG PLC, MERCK AND CO., SIGMA ALDRICH, MICROPHARM and BOEHRINGER-INGELHEIM
REASONS TO PURCHASE THIS REPORT
• Market analysis for the Global Antivenom Market, with region-specific assessments and competition analysis on a global and regional scale.
• Analyzing various perspectives of the industry with the help of Porter’s five forces analysis
• The treatment type that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares and strategies employed by the major market players.
• 3 months analyst support along with the Market Estimate sheet in excel.
CUSTOMIZATION OF THE REPORT
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
レポート目次TABLE OF CONTENTS
1. INTRODUCTION
1.1 MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW
5.1 CURRENT MARKET SCENARIO
5.2 PORTERS FIVE FORCES
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF CONSUMERS
5.2.3 THREATS OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 MARKET DRIVERS
6.1.1 RECENT ADVANCEMENTS IN PHARMACEUTICALS
6.1.2 INCREASING AWARENESS ON ANTIVENOMS AVAILABLE
6.2 MARKET RESTRAINTS
6.2.1 HIGH COST OF ANTIVENOM AVAILABLE
6.2.2 PREPARATION OF THE CORRECT IMMUNOGENS (SNAKE VENOMS)
6.2.3 LACK OF REGULATORY CAPACITY FOR THE CONTROL OF ANTIVENOMS IN COUNTRIES
6.2.4 WEAK HEALTH SYSTEMS AND LACK OF DATA
6.3 OPPORTUNITIES
6.4 KEY CHALLENGES
7. MARKET SEGMENTATION
7.1 SEGMENTATION BY ANIMALS
7.1.1 SNAKES
7.1.2 SCORPION
7.1.3 SPIDERS
7.1.4 OTHERS
7.2 SEGMENTATION BY TYPE
7.2.1 POLYVALENT HETEROLOGOUS ANTIVENOMS
7.2.2 MONOVALENT HETEROLOGOUS ANTIVENOMS
7.2.3 HOMOLOGOUS ANTIVENOMS:
7.2.4 SMALL MOLECULE ANTI-TOXINS
7.3 SEGEMENTATION BY GEOGRAPHY
7.3.1 NORTH AMERICA
7.3.1.1 UNITED STATES
7.3.1.2 CANADA
7.3.1.3 MEXICO
7.3.2 EUROPE
7.3.2.1 FRANCE
7.3.2.2 GERMANY
7.3.2.3 UNITED KINGDOM
7.3.2.4 ITALY
7.3.2.5 SPAIN
7.3.2.6 REST OF EUROPE
7.3.3 ASIA-PACIFIC
7.3.3.1 CHINA
7.3.3.2 JAPAN
7.3.3.3 INDIA
7.3.3.4 AUSTRALIA & NEW ZEALAND
7.3.3.5 SOUTH KOREA
7.3.3.6 REST OF ASIA-PACIFIC
7.3.4 MIDDLE EAST AND AFRICA
7.3.4.1 GCC
7.3.4.2 SOUTH AFRICA
7.3.4.3 REST OF MIDDLE EAST AND AFRICA
7.3.5 SOUTH AMERICA
7.3.5.1 BRAZIL
7.3.5.2 ARGENTINA
7.3.5.3 REST OF SOUTH AMERICA
8. COMPETITIVE LANDSCAPE
8.1 MERGERS AND ACQUISITION ANALYSIS
8.2 AGREEMENTS, COLLABORATIONS & PARTNERSHIPS
8.3 NEW PRODUCTS LAUNCHES
9. COMPANY PROFILES
9.1 PFIZER INC
9.2 BIOCLON INSTITUTE
9.3 CSL LIMITED
9.4 BTG PLC
9.5 MERCK AND CO.
9.6 SIGMA ALDRICH
9.7 MICROPHARM
9.8 BOEHRINGER-INGELHEIM
9.9 OTHERS
10. FUTURE OUTLOOK OF THE MARKET